Decibel Therapeutics

93 articles about Decibel Therapeutics

• Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

  9/25/2023

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs.

• Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

  8/11/2023

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

  8/9/2023

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. today announced a definitive agreement for the acquisition of Decibel by Regeneron at a price of $4.00 per share of Decibel common stock payable in cash at closing.

• 

  Regeneron Buys Decibel’s Hearing Loss Gene Therapies in $109M Deal

  8/9/2023

  The acquisition will bring gene therapy company Decibel Therapeutics into Regeneron’s fold after a six-year partnership, targeting different forms of congenital and monogenic hearing loss.

• Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference

  6/2/2023

  Decibel Therapeutics today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 12:45 p.m. E.T in New York, NY.

• Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

  6/1/2023

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, June 2-6, 2023.

• Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit

  5/17/2023

  Decibel Therapeutics (Nasdaq: DBTX) today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Barclays 2023 Gene Editing and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30 a.m. E.T being held virtually.

• Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

  5/15/2023

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO

  5/12/2023

  Decibel Therapeutics announced approval of its Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

• Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

  5/10/2023

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

• Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO

  3/30/2023

  Decibel Therapeutics today announced that the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) has issued a positive opinion on orphan drug designation for DB-OTO, Decibel’s lead gene therapy product candidate designed to provide durable, high quality, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of the otoferlin gene.

• Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

  3/28/2023

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 9:00 a.m. E.T in New York, NY.

• Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

  3/21/2023

  Decibel Therapeutics today announced the appointment of Matthew Kapusta to its Board of Directors.

• Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

  3/14/2023

  Decibel Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference

  2/16/2023

  Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16, 2023 at 9:20 a.m. E.T.

• Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

  2/9/2023

  Decibel Therapeutics today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

• Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO

  1/24/2023

  Decibel Therapeutics today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

• Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Update

  11/9/2022

  Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Decibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTO

  11/2/2022

  Decibel Therapeutics announced the submission of Clinical Trial Applications to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom and the Spanish Agency of Medicines and Medical Devices for a Phase 1/2 clinical trial in pediatric patients of DB-OTO, a gene therapy product candidate designed to provide durable hearing in individuals with profound congenital hearing loss due to an otoferlin deficiency.

• Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss

  10/17/2022

  Decibel Therapeutics today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is designed to provide durable hearing in individuals born with profound congenital hearing loss due to an otoferlin deficiency.